Restoration of dendritic cell homeostasis and Type I/Type III interferon levels in convalescent COVID-19 individuals

Anuradha Rajamanickam1†, Nathella Pavan Kumar2†, Arul Nancy Pandiaraj1, Nandhini Selvaraj1, Saravanan Munisankar1, Rachel Mariam Renji1, Vijayalakshmi Venkatramani1, Manoj Murhekar3, Jeromie Wesley Vivian Thangaraj3, Muthusamy Santhosh Kumar3, Chethrapilly Purushothaman Girish Kumar3, Tarun Bhatnagar3, Manickam Ponnaiah3, Ramasamy Sabarinathan3, Velusamy Saravanakumar3 and Subash Babu1

Abstract
Background: Plasmacytoid and myeloid dendritic cells play a vital role in the protection against viral infections. In COVID-19, there is an impairment of dendritic cell (DC) function and interferon secretion which has been correlated with disease severity.

Results: In this study, we described the frequency of DC subsets and the plasma levels of Type I (IFNα, IFNβ) and Type III Interferons (IFNλ1, IFNλ2 and IFNλ3) in seven groups of COVID-19 individuals, classified based on days since RT-PCR confirmation of SARS-CoV2 infection. Our data shows that the frequencies of pDC and mDC increase from Days 15–30 to Days 61–90 and plateau thereafter. Similarly, the levels of IFNα, IFNβ, IFNλ1, IFNλ2 and IFNλ3 increase from Days 15–30 to Days 61–90 and plateau thereafter. COVID-19 patients with severe disease exhibit diminished frequencies of pDC and mDC and decreased levels of IFNα, IFNβ, IFNλ1, IFNλ2 and IFNλ3. Finally, the percentages of DC subsets positively correlated with the levels of Type I and Type III IFNs.

Conclusion: Thus, our study provides evidence of restoration of homeostatic levels in DC subset frequencies and circulating levels of Type I and Type III IFNs in convalescent COVID-19 individuals.

Keywords: Dendritic cell subsets, pDC, mDC, Type I IFNs, Type III IFNs, COVID-19, Acute and convalescent COVID-19

Background
Among innate immune cells which have a critical role in the anti-SARS-CoV-2 immune response, one of the main players are the dendritic cells (DCs) [1]. SARS-CoV-2 infection induces an impairment in the functions of interferons (IFNs), antigen presentation and decreased numbers of DCs in the peripheral blood [2]. Several reports indicated that the DC numbers were diminished due to infection in peripheral blood and it is associated with the severity of this disease [3, 4]. This decrease could be due to the migration of DC subsets to the lung and other inflammatory loci [5, 6], enhanced apoptosis of DCs and the suppressive consequences of myeloid-derived suppressor cells [7]. Type I IFNs play an important role in viral infections [8] and major producers of Type I IFNs have a crucial function in COVID-19. Also, various studies have shown that severe patients were associated...
with decreased IFN responses [9, 10]. Several reports determined that SARS-CoV-2 affects pDCs by producing IFN-I [7]. However, the function of DC subsets and Type I and III IFNs in acute and convalescent SARS-CoV-2 individuals are not completely explored.

Following COVID-19, the restoration of DC impairment might be essential, because the stabilization of the innate immune system is required for return to homeostasis. This recovery is essential in terms of return to normality of innate immune responses as DCs and Type I/III interferons are important in the prolonged protection [11]. Hence, we wanted to study the frequencies of DC subsets and circulating levels of Type I and Type III IFNs in convalescent COVID-19 individuals more than 150 days after infection following RT PCR confirmation.

Results
Study population characteristics
Demographics and clinical characteristics of the study population are shown in Tables 1 and 2 as previously described [12–14]. The median age ranges from 36—45.5 years among the groups. In all the groups, the female number was slightly higher than the number of male patients. However, they are not statistically different among the groups. Individuals with Hypertension were 26% in the acute phase group and in the remaining groups i.e., 31–60 days to more than 180 days, the percentage ranged from 18 to 30%. Individuals with Diabetes Mellitus were 19% in the acute phase and in the remaining groups i.e., 31–60 days to more than 180 days, the percentage ranged from 19 to 30%. Individuals with Asthma were 5% in the acute phase and in the remaining groups i.e., 31–60 days (6%), 61–90 days (3%), 91–120 days (3%) and 151–180 days (3%). The other clinical symptoms such as fever, cough, chills, sore throat, runny nose, loss of taste and smell, muscle aches, joint pain, abdominal pain, vomit, and diarrhoea were present almost in all the groups. Individuals with seizures were 3% in 31–60 days alone and Neuro related disorders were 5% in the 61–90 days group alone. 3% of chronic kidney diseases were in 91–120 days and more than 180 groups of individuals. 15–30 days (6%), 31–60 days (3%) and 61–90 days (3%), 7% of the severely infected were with heart diseases. Individuals with rheumatic fever were 3% in 61–90 days and 151–180 days (3%). Individuals treated with corticosteroids were 15–30 days (9%), 31–60 days (9%) and 61–90 days (5%), 91–120 days (10%), 121–150 days (3%) and 151–180 days (3%) and severe (20%). Individuals treated with antiviral drugs were 15–30 days (9%), 31–60 days (15%) and 61–90 days (5%), and 91–120 days (13%) and severe (27). Among the severely infected group, 40% of them required hospitalization. We wanted to examine the Type1 and Type III IFN kinetics following RT-PCR confirmation from days 15–30 to more than 180 days. To this end, we combined all the groups irrespective of their disease status (mild, moderate, severe and convalescence) [12–15].

Increased frequencies of dendritic cell subsets and circulating levels of Type I and Type III IFNs in convalescent COVID-19 individuals over time
To determine the frequencies and distribution of dendritic cell subsets in convalescent COVID-19 individuals over time, we assessed the ex-vivo frequencies of dendritic cell subsets (pDC and mDC) in the seven groups of COVID-19 individuals. As illustrated in Fig. 1A, and the gating strategy was shown in supply. Fig. S1 (Additional File 1) the frequencies of pDCs and mDCs started increasing from day 15–30 till 91–120 days (first-order model polynomial model fit curve, intermediate monocytes R = 0.29, non-classical monocytes R = 0.42 by Akaike’s Information Criterion) and plateaued thereafter.

Next, we wanted to examine the levels of Type I and Type III IFNs in convalescent COVID-19 individuals over time, we assessed the plasma levels of Type I (IFNa, IFNβ), Type III (IFNα1, IFNα2 and IFNα3) in the seven groups of COVID-19 individuals. As illustrated in Fig. 1B and C, the cross-sectional analysis demonstrated that the levels of Type I and Type III started increasing from days 15–30 (second-order model polynomial model fit curve, IFNa, R = 0.28, IFNβ, R = 0.34, IFNα1, R = 0.39, IFNα2, R = 0.32 and IFNα3 R = 0.52 by Akaike’s Information Criterion) till 151 days after infection.

As shown in Additional file 2: Figure 2, the comparative analysis also exhibited significant differences between seven-time point intervals. Both the DC subsets and the circulating levels of Type I and III IFNs showed a gradual and steady increase from days 15–30 to till 150 days and then it started to plateau. The 95% of confidence intervals were shown in Additional file 3: Table 1. Thus, plasma levels of Type I and Type III IFNs are increased over time.

Severe COVID-19 disease is associated with decreased frequencies of DC subsets and circulating levels of Type I and Type III IFNs
Next, we wanted to determine the frequencies of DC subsets in mild and severely diseased COVID-19 individuals. As shown in Fig. 2A, the frequencies of pDC (GM of 0.60% in mild, 0.18% in severe) and mDC (GM of 3.12% in mild, 0.1% in severe) were significantly lower in severe than the mild COVID-19 individuals. Further, we analysed the effect of COVID-19 disease severity on circulating levels of Type I and Type III IFNs. As shown in Fig. 2B, the levels of IFNa (GM of 456.4 pg/ml in mild, 196.3 pg/ml in severe), IFNβ (GM of 234.7 pg/ml in mild, 47.48 pg/ml in severe) and Type III IFNs (GM of 234.7 pg/ml in mild, 47.48 pg/ml in severe) were shown in Additional file 3: Table 1.
severe). As shown in Fig. 2C, IFNλ1 (GM of 1013 pg/ml in mild, 515 pg/ml in severe), IFNλ2 (GM of 961.7 pg/ml in mild, 559.1 pg/ml in severe) and IFNλ3 (GM of 382 pg/ml in mild, 241 pg/ml in severe) were significantly lower in severe than the mild COVID-19 individuals. Thus, severe COVID-19 disease is associated with decreased frequencies of DC subsets and diminished circulating levels of Type I and Type III IFNs.

**Association between DC subsets and the levels of Type I and Type III IFNs**

Next, we wanted to determine the relationship between DC subsets and the levels of Type I and Type III IFNs in mild and severe groups of COVID-19 individuals. As shown in Fig. 3A, mild COVID-19 individuals exhibited a positive correlation between the percentages of DC subsets and the levels of Type I and
Type III IFNs. Similarly, severe COVID-19 individuals also exhibited a positive correlation between the percentages of pDC subsets and the levels of Type I and Type III IFNs and the mDCs showed a positive correlation with the levels of IFNβ and IFNλ1 alone (Fig. 3B). Thus, mild and severe COVID-19 individuals exhibited a positive correlation among DC subsets and levels of Type I and Type III IFNs.
Discussion

DCs play a role in the presentation of antigens, production of cytokines, regulation of inflammatory responses, stimulation of tolerance, immune cell enrolment, and viral spreading [1]. DC frequency and numbers are correlated with the disease severity in COVID-19 [4]. Delayed activation of DC could lead to delayed initiation of adaptive immune response to pathogens. IFN is secreted by diverse cell types and capable of regulating the innate and adaptive immune response [8, 16]. Numerous studies have shown that severe SARS-CoV-2 patients are correlated with lessened numbers of mDCs and pDCs [1, 4, 5]. In our study, both DC subsets started expanding from day 15–30 till 91–120 days and plateaued thereafter. Our study corroborates previous findings that DC subsets were reduced in severe COVID-19 than the mild patients. This decrease could be due to augmented migration from the blood and sequestration in tissues, such as the inflamed lung or lymphoid tissues [17].

Numerous reports determined that Type I and III IFN responses are suppressed during the early phase of the infection in severe COVID-19 patients [2]. pDCs are recognized to play a vital function in the first line of defence in anti-viral simulation, with the capacity to produce IFN-I and III [18, 19]. The reduction of DC subsets could be due to the impairment of myeloid cell functionality [20] and impaired maturation of the DC process that hinders DC homing, and antigen presentation and eventually delay an effective T-cell response [21]. Zhou et al. reported that the capability of DCs to produce pro-inflammatory cytokines and IFN-I was inhibited in COVID-19 patients (Zhou R, Immunity, 2020). An IFN-I deficit supports SARS-CoV-2 to escape leading to the secretion of several ineffective antiviral proinflammatory cytokines which could provoke the cytokine storm [7]. During COVID-19, Type I and III interferon responses were induced in the initial period of infection in regulating the COVID-19 sequence [22]. Individuals with a deficiency in Type I interferon signalling are more susceptible to developing severe COVID-19 (coronavirus disease 2019) disease [23, 24]. Preexisting auto-Abs neutralizing Type I IFNs in APS-1 patients renders them more vulnerable to a massive chance of severe COVID-19 pneumonia across the lifespan [25]. Our data exhibited that expansion of Type I and Type III IFNs from day 15–30 till 120 days and plateaued thereafter. Also, Severe COVID-19 patients exhibited decreased Type I and Type III IFNs. Also, there was a significant positive correlation between the DC subsets and levels of Type I and III IFNs. In this study, we perceived a positive correlation between DC subsets and IFN levels implying that these cell types were the major source of these cytokines as occurs in other viral illnesses [26]. These results corroborates with earlier studies in the SARS-CoV-1 animal models [27] and also with the latest report on the transcriptomic approach [28]. Marongiu et. al. reported that SARS-CoV-2 directly interrelates with conventional DC2s and devices an effective immune escape mechanism that is associated with the severity of disease via downregulating key molecules mandatory for the triggering of T-cells [29]. These data underpin the vital function of IFN-1 secretion in the first line of protection against COVID-19.

Our study has the constraint of not examining the functional effect of these modifications in cellular subsets and IFN pathways. Another limitation is the lack of a healthy control group in our study and that our study was cross-sectional and not longitudinal. We enrolled different individuals in each of the seven categories and did not perform follow-up of the same patients at various time points. However, our study offers an extensive interrogation of DC subsets and levels of IFNs from early to more than 6 months post-infection and disease severity. Our study therefore imply vital changes in DC subsets and IFNs as one of the major occurrence in COVID-19.
Conclusions
In summary, our study suggests that DC subsets and the levels of Type I and III levels were diminished in the individuals with SARS-CoV-2 at early time points following infection. The DC subsets and the levels of Type I and III were gradually restored more than 6 months after the infection. These results could support a major effect on the type of immune responses in COVID-19. Also, our results imply that Type I and III IFN diminution might be a characteristic feature of COVID-19 and provide a basis for combined therapeutic approaches.

Methods

Study population
Acute COVID-19 (15–30 days from RT-PCR confirmation, n = 46) and Convalescent COVID-19 individuals (classified by days after infection as 31–60, n = 33; 61–90, n = 38; 91–120, n = 34; 121–150, n = 32; 151–180, n = 37 and more than 180, n = 40), residing in Chennai and Tiruvallur were enrolled in the study between November 2020 and December 2020 after taking informed consent from the study individuals. This was a cross-sectional study and different individuals were enrolled in the different categories. Those individuals who did not experience any symptoms during the entire course of illness were considered asymptomatic and those who required supplemental oxygen support therapy or those who were admitted to ICU for oxygen support were considered severely ill. Rest were classified under the mild illness category (11–14).

Haematology
Haematology was performed on all individuals using the Act-5 Diff haematology analyzer (Beckman Coulter). Demographic details and other clinical parameters were shown in Table 1.

| Table 1 | Demographics and clinical parameters of the study population |
|---------|------------------------------------------------------------|
| Days after RT-PCR confirmation | 15–30 days | 31–60 days | 61–90 days | 91–120 days | 121–150 days | 151–180 days | More than 180 days |
| Subjects enrolled | n = 46 | n = 33 | n = 38 | n = 34 | n = 32 | n = 37 | n = 40 |
| Median age (range) | 41.5 (18–70) | 36 (25–68) | 45 (19–59) | 45 (21–69) | 45.5 (27–59) | 42 (23–58) | 38.5 (21–78) |
| Gender (M/F) | 27/19 | 17/18 | 22/15 | 22/12 | 14/18 | 23/16 | 26/14 |
| Fever, no. (%) | 29 (67%) | 22 (65%) | 21 (52%) | 19 (56%) | 20 (62%) | 17 (53%) | 17 (47%) |
| Chills, no. (%) | 9 (21%) | 5 (15%) | 2 (5%) | 7 (22%) | 4 (13%) | 1 (3%) | 3 (8%) |
| Cough, no. (%) | 21 (49%) | 20 (59%) | 15 (39%) | 12 (36%) | 11 (33%) | 12 (36%) | 12 (33%) |
| Sore throat, no. (%) | 21 (49%) | 12 (34%) | 15 (36%) | 12 (37%) | 10 (30%) | 16 (50%) | 13 (36%) |
| Runny nose, no. (%) | 7 (16%) | 6 (18%) | 5 (13%) | 0 | 3 (10%) | 1 (3%) | 5 (14%) |
| Taste loss, no. (%) | 24 (55%) | 14 (41%) | 17 (44%) | 12 (39%) | 11 (33%) | 20 (63%) | 12 (33%) |
| Smell loss, no. (%) | 21 (49%) | 14 (41%) | 21 (55%) | 9 (29%) | 11 (33%) | 16 (50%) | 10 (28%) |
| Muscle ache, no. (%) | 23 (53%) | 20 (59%) | 29 (76%) | 15 (48%) | 18 (60%) | 21 (66%) | 13 (36%) |
| Joint pain, no. (%) | 20 (49%) | 18 (53%) | 20 (53%) | 10 (32%) | 18 (60%) | 14 (44%) | 9 (25%) |
| Abdominal pain, no. (%) | 3 (7%) | 3 (9%) | 4 (11%) | 2 (6.5%) | 3 (10%) | 2 (7%) | 3 (8%) |
| Vomit, no. (%) | 3 (7%) | 4 (12%) | 5 (13%) | 4 (13%) | 3 (10%) | 5 (16%) | 3 (8%) |
| Diarrhea, no. (%) | 10 (23%) | 5 (15%) | 4 (11%) | 4 (13%) | 6 (30%) | 5 (16%) | 2 (6%) |
| Seizures, no. (%) | 0 | 1 (3%) | 0 | 0 | 0 | 0 | 0 |
| Hypertension, no. (%) | 11 (26%) | 7 (21%) | 7 (18%) | 7 (23%) | 9 (30%) | 9 (28%) | 8 (22%) |
| Diabetes, no. (%) | 8 (19%) | 7 (21%) | 11 (30%) | 9 (29%) | 11 (37%) | 8 (25%) | 7 (19%) |
| Asthma, no. (%) | 2 (5%) | 2 (6%) | 1 (3%) | 1 (3%) | 0 | 1 (3%) | 0 |
| Chronic kidney disease, no. (%) | 0 | 0 | 0 | 0 | 1 (3%) | 0 | 1 (3%) |
| Neuro, no. (%) | 0 | 0 | 2 (5%) | 0 | 0 | 0 | 0 |
| Cancer, no. (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Heart, no. (%) | 1 (6%) | 2 (3%) | 1 (3%) | 0 | 0 | 1 (3%) | 0 |
| Rheumatic fever, no. (%) | 0 | 0 | 1 (3%) | 0 | 0 | 1 (3%) | 0 |
| Corticosteroids, no. (%) | 4 (9%) | 3 (9%) | 2 (5%) | 3 (10%) | 1 (3%) | 1 (3%) | 0 |
| Antiviral drug, no. (%) | 4 (9%) | 5 (15%) | 2 (5%) | 4 (13%) | 0 | 0 | 0 |
| Immunomodulator, no. (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Table 2 Demographics and clinical parameters of the study population

| Parameters                                | Mild                  | Severe     |
|-------------------------------------------|-----------------------|------------|
| Subjects enrolled                         | n = 30                | n = 15     |
| Median age (range)                        | 39 (18–81)            | 48 (22–70) |
| Gender (M/F)                              | 14/16                 | 12/3       |
| Fever, no. (%)                            | 17 (57)               | 13 (87)    |
| Chills, no. (%)                           | 4 (13)                | 6 (40)     |
| Cough, no. (%)                            | 15 (50)               | 7 (47)     |
| Sore throat, no. (%)                      | 16 (53)               | 5 (33)     |
| Runny nose, no. (%)                       | 5 (17)                | 2 (13)     |
| Taste loss, no. (%)                       | 21 (70)               | 5 (33)     |
| Smell loss, no. (%)                       | 17 (57)               | 6 (40)     |
| Muscle aches, no. (%)                     | 24 (80)               | 9 (60)     |
| Joint pain, no. (%)                       | 18 (60)               | 5 (33)     |
| Abdominal pain, no. (%)                   | 2 (7)                 | 1 (7)      |
| Vomit, no. (%)                            | 2 (7)                 | 1 (7)      |
| Diarrhea, no. (%)                         | 4 (13)                | 6 (40)     |
| Seizures, no. (%)                         | NIL                   | NIL        |
| Hypertension, no. (%)                     | 7 (23)                | 5 (33)     |
| Diabetes, no. (%)                         | 4 (13)                | 4 (27)     |
| Asthma, no. (%)                           | 1 (3)                 | 1 (7)      |
| Chronic kidney disease, no. (%)           | NIL                   | NIL        |
| Neuro, no. (%)                            | NIL                   | NIL        |
| Heart, no. (%)                            | NIL                   | 1 (7)      |
| Rheumatic fever, no. (%)                  | NIL                   | NIL        |
| Corticosteroids, no. (%)                  | NIL                   | 3 (20)     |
| Antiviral drug, no. (%)                   | NIL                   | 4 (27)     |
| Required hospitalization no. (%)          | NIL                   | 6 (40)     |
| Required mechanical oxygen support no. (%)| NIL                   | NIL        |

Immunophenotyping and measurement of Type I and III IFNs

Ex vivo phenotyping was done using whole blood. Briefly, to 250 µl aliquots of whole blood, a cocktail of monoclonal antibodies specific for DC subsets were added, incubated, washed and acquired. The gating was set by forward and side scatter, and 500,000 gated events were acquired. Compensation and gating boundaries were adjusted using unstained, single stained, and Fluorescence Minus One (FMO) control. IFNα and IFNβ levels were measured using VeriKine-Human Interferon Alpha All Subtype and Beta ELISA kits (PBL Interferon sources). IFNα1, IFNα2 and IFNα3 were measured using the Duo Set ELISA kit (R&D Systems).

Statistical analysis

Cross-sectional analysis of the frequency of dendritic cell subsets and haematology analysis were performed using the polynomial model for the best fit curve (either first-order or second-order model). By way of modelling analysis, first-order or second-order model polynomial function was shown to be the best model amongst the diverse polynomials examined. Mild versus severe statistically significant differences were calculated by the non-parametric Mann–Whitney U test. Flowjo 10.8.0, GraphPad PRISM version 9 (GraphPad Software, Inc.) were used for the data analyses. Correlation analyses were performed using JMP 16 (SAS).

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12865-022-00526-z.

Additional file 1. Fig. S1. Gating Strategy for DC subsets.

Additional file 2. Fig. S2. Analysis of DC subsets, Type I and Type III from acute and convalescent COVID-19 individuals classified as groups based on days since RT-PCR confirmation.

Additional file 3. Table S1. 95% of CI of DC subsets and Type I and III IFNs.

Acknowledgements

We thank the Director of the NIRT for the constant support. We thank the data entry operators Mr. M. Jaiganesh and Mr. R. Vigneshwiran, and also all the staff members of the ICER and Immunology department for the timely help. We thank the staff nurse M Beula Margarete, Technical Officers C.K. Sathish Kumar, Annamma Jose, D Augustine, C. Prabakaran, Technical Officers B.P. Ashok Kumar and laboratory technician T. Mahesh, S. Kalaivanai, M. Sheeba Mary, C. Kanagasivam, Technical Assistant R. Sivakumar, Project Assistants Y Radhakrishnaiyah, R. Swapna Shinde.

Author contributions

Designed the study (S.B., A.R, N.P.K.); conducted experiments (A.R., N.P.K., A.N., N.S., R.M.R, V.V); acquired data (A.R, N.P.K.); analysed data (A.R., N.P.K.); contributed reagents and also revised subsequent drafts of the manuscript (S.B., M.M); responsible for the enrolment of the participants and also contributed to acquisition and interpretation of clinical data (M.M., J.W.V.T, CP G.K); coordinated field operations (M.M., J.W.V.T, M.S.K., T.B., M.P .), coordinated the laboratory processing of samples (CP G.K), coordinated data management (P.S., V.S.); wrote the manuscript (A.R., S.B.). All authors read and approved the final manuscript.

Funding

This work was supported by ICMR-NIRT-ICER and ICMR-NIE.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committees of National Institute for Research in Tuberculosis (NIRT-Ino:2020047) and National Institute of Epidemiology (NIE/HEC/202008–01). All the protocols were followed in consonance with the relevant institutional ethical committee guidelines.

Informed consent

Informed written consent was obtained from all participants. All the methods were performed by the relevant institutional ethical committee guidelines.

Consent for publication

Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1 ICER-ICMR-NIRT-International Center for Excellence in Research, Chennai, Tamil Nadu, India. 2 Immunology-ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India. 3ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.

Received: 25 April 2022 Accepted: 13 October 2022 Published online: 26 October 2022

References
1. Perez-Gomez A, Vitalle J, Gasca-Capote C, Gutierrez-Valencia A, Trujillo-Rodriguez M, Serna-Gallo A, et al. Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol Immunol. 2021.
2. Park A, Iwasaki A. Type I and Type III interferons - induction, signal- ing, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870–8.
3. Kvedaraite E, Hertwig L, Sinha I, Ponzetta A, Hed Myrberg I, Lourda M, et al. Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. Proc Natl Acad Sci U S A. 2021;118(6).
4. Zhou R, To KK, Wong YC, Lu L, Zhou B, Li X, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T Cell Responses. Immunology. 2020;53(4):864–77.
5. Sanchez-Cerrillo I, Landete P, Aldave B, Sanchez-Alonso S, Sanchez-A佐佐 A, Marcos-JimeNEZ A, et al. COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes. J Clin Invest. 2020;130(12):6290–300.
6. Perez-Gomez A, Vitalle J, Gasca-Capote C, Gutierrez-Valencia A, Trujillo-Rodriguez M, Serna-Gallo A, et al. Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol Immunol. 2021;18(9):2128–39.
7. Chang T, Yang J, Deng H, Chen D, Yang X, Tang ZH. Depletion and dysfunction of dendritic cells: understanding SARS-CoV-2 infection. Front Immunol. 2022;13:843342. https://doi.org/10.3389/fimmu.2022.843342.
8. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918–21.
9. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234(1):142–62.
10. Arunachalam PS, Wimmers F, Mok CHP, Perera R, Scott M, Hagan T, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369(6608):1210–20.
11. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–5.
12. Rajamanickam A, Kumar MP, Pandarajan AN, Selvaraj N, Munisankar S, Renji RM, et al. Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals. Sci Rep. 2021;11(1):20254.
13. Rajamanickam A, Pavan Kumar N, Pandiarajan AN, Selvaraj N, Munisankar S, Renji RM, et al. Characterization of memory T cell subsets and common gamma-chain cytokines in convalescent COVID-19 individuals. J Leukoc Biol. 2022;112(1):201–12.
14. Rajamanickam A, Kumar NP, Nancy PA, Selvaraj N, Munisankar S, Renji RM, et al. Recovery of memory B-cell subsets and persistence of antibodies in convalescent COVID-19 patients. Am J Trop Med Hyg. 2021;105(5):1255–60.
15. Rajamanickam A, Munisankar S, Bhootra Y, Dolla C, Nutman TB, Babu S. Elevated systemic and parasite-antigen stimulated levels of Type III IFNs in a chronic helminth infection and reversal following anthelmintic treatment. Front Immunol. 2018;9:2353.
16. Soto JA, Galvez NMS, Andrade CA, Pacheco GA, Bohmwald K, Berrios RV, et al. The role of dendritic cells during infections caused by highly prevalent viruses. Front Immunol. 2020;11:1513.
17. Wintheim E. Impaired function and delayed regeneration of dendritic cells in COVID-19. bioRxiv preprint 2021.
18. Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019;50(1):37–50.
19. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol. 2012;189(6):2735–45.
20. Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L, Vanni A, Orazzini C, Nozzoli C, Morettini A, Poggies L, Periali F, Peris A, Bartoloni A, Vannucchi AM, Liotta F, Caporale R, Cosimi L, Arranziazo F. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology. 2020;161(4):345–53. https://doi.org/10.1111/imm.13254.
21. Borchertling E, Tienen AN, Grosser B, Schaller T, Hirschbhühl K, Claus R, Spring O, Wittmann M, Rommele C, Sipos E, Märlk B. Impaired dendritic cell homing in COVID-19. Front Med (Lausanne). 2021;4(8):761372. https://doi.org/10.3389/fmed.2021.761372.
22. Kim MH, Salloum S, Wang JY, Lai Ping W, Regan J, Leffteri K, et al. Type I, II, and III interferon signatures correspond to COVID-19 disease severity. J Infect Dis. 2021.
23. Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eab4340. https://doi.org/10.1126/sciimmunol.ab4340.
24. Bastard P, Roslen LB, Zhang Q, et al. Autoantibodies against cytokines and III IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218(7):e20210554. https://doi.org/10.1084/jem.20210554.
25. Machnach K, Leal M, Gras C, Viciana P, Genebat M, Franco E, et al. Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol. 2017;86(8):4245–52.
26. Channapanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–93.
27. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Preexisting autoantibodies to type I and II IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. https://doi.org/10.1126/science.abd4585.
28. Bastard P, Orlova E, Sozaev L, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218(7):e20210554. https://doi.org/10.1084/jem.20210554.
29. Marongiu L, Protti G, Facchini FA, et al. Maturation signatures of conventional dendritic cell subsets in COVID-19 patients. Science. 2020;369(6504):718–24.
30. Marongiu L, Protti G, Facchini FA, et al. Maturation signatures of conventional dendritic cell subsets in COVID-19 patients. Science. 2020;369(6504):718–24.
31. Spring O, Wittmann M, Rommele C, Sipos E, Märlk B. Impaired dendritic cell homing in COVID-19. Front Med (Lausanne). 2021;4(8):761372. https://doi.org/10.3389/fmed.2021.761372.
32. Hammad H, Tian J, Arai H, et al. Type I and Type III interferons are produced by and stimulate human plasmacytoid dendritic cells. J Immunol. 2012;189(6):2735–45.
33. Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L, Vanni A, Orazzini C, Nozzoli C, Morettini A, Poggies L, Periali F, Peris A, Bartoloni A, Vannucchi AM, Liotta F, Caporale R, Cosimi L, Arranziazo F. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology. 2020;161(4):345–53. https://doi.org/10.1111/imm.13254.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.